CEO letter
For the benefit of the 2.5% recently joined shareholders, I distinguish CLINUVEL’s...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
Notice of ceasing to be a substantial holder
Melbourne, Australia, 27 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Initial Director’s Interest Notice
Melbourne, Australia, 7 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL appoints new Non-Executive Director
Melbourne, Australia, 04 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Change of Director's Interest Notice
Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Change of Director's Interest Notice
Melbourne, Australia, 02 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CEO letter
On 24 February, the world plunged into instability, initiated by delusional warfare...
Read More
CLINUVEL Reports Record December Half Year Operating Profit
Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Appendix 4D - ASX Listing Rule 4.2A.3 Half Yearly Report
Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Financial Results Half Year Ended, 31 December 2021
CLINUVEL PHARMACEUTICALS LTD announced today the financial results for the half year...
Read More
Appendix 4C & Activity Report
Melbourne, Australia, 31 January 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 19 January 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Notification of Cessation of Securities
Melbourne, Australia, 19 January 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Results of Annual General Meeting 2021
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read More